Outcome at 3 years with a prednisone-free maintenance regimen: A single-center experience with 349 kidney transplant recipients

American Journal of Transplantation

Volumn 4, Issue 6, 2004, Pages 980-987

  Khwaja, Khalid ^a   Asolati, Massimo ^a   Harmon, James ^a   Melancon, J Keith ^a   Dunn, Ty ^a   Gillingham, Kristen ^a   Kandaswamy, Raja ^a   Humar, Abhinav ^a   Gruessner, Rainer ^a   Payne, William ^a   Najarian, John ^a   Dunn, David ^a   Sutherland, David ^a   Matas, Arthur J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Kidney transplant; Steroid free

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; DACLIZUMAB; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; AVASCULAR NECROSIS; CATARACT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRACTURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; SKIN CANCER; STEROID THERAPY;

ANTILYMPHOCYTE SERUM; CASE-CONTROL STUDIES; CREATININE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NECROSIS; PREDNISONE; SIROLIMUS; TIME FACTORS;

EID: 2942566086     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00443.x     Document Type: Article

References (43)

1. Citterio F. Steroid side effects and their impact on transplantation outcome. Transplantation 2001; 72: S75-80.
2. Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33: 829-839.
3. Schweizer RT, Rovelli M, Palmeri D, Vossler E, Hull D, Bartus S. Noncompliance in organ transplant recipients. Transplantation 1990; 49: 374-377.
4. Nevins TE, Kruse L, Skeans MA, Thomas W. The natural history of azathioprine compliance after renal transplantation. Kidney Int 2001; 60: 1565-1570.
5. Montagnino G, Tarantino A, Maccario M, Elli A, Cesana B, Ponticelli C. Long-term results with cyclosporine monotherapy in renal transplant patients: a multivariate analysis of risk factors. Am J Kidney Dis 2000; 35: 1135-1134.
6. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992; 147: 645-657.
7. Hricik DE, O'Toole MA, Schulak JA, Herson J. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993; 4: 1300-1305.
8. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. Am Soc Nephrol 2000; 11: 1910-1917.
9. Ahsan N, Hricik D, Matas A et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68: 1865-1874.
10. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70: 1352-1359.
11. Matas AJ. Acute rejection is a major risk factor for chronic rejection. Transplant Proc 1998; 30: 1766-1768.
12. Lo Cascio V, Bonucci E, Imbimbo B et al. Bone loss after glucocorticoid therapy. Calcif Tissue Int 1984; 36: 435-438.
13. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993; 119: 963-968.
14. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39: 1383-1389.
15. Gluck OS, Murphy WA, Hahn TJ, Hahn B. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum 1981; 24: 892-898.
16. Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983; 25: 615-620.
17. Birkeland SA. Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Transplantation 2001; 71: 1089-1090.
18. Matas AJ, Ramcharan T, Paraskevas S et al. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant 2001; 1: 278-283.
19. Kandaswamy R, Humar A, Khwaja K et al. A prospective, randomized study of cyclosporine/CellCept vs. tacrolimus/sirolimus with rapid discontinuation of prednisone (Abstract). Am J Transplant 2003; 3: 198.
20. Kaufman DB, Leventhal JR, Fryer JP et al. Kidney transplantation without prednisone (Abstract). Transplantation 2000; 69: S133.
21. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306-311.
22. Leventhal JR, Kaufman DB, Lorenzo G et al. Four-year single center experience with prednisone-free immunosuppression in 434 kidney transplant recipients (Abstract). Am J Transplant 2003; 3: 439.
23. Cole E, Landsberg D, Russell D et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001; 72: 845-50.
24. Sarwal MM, Yorgin PD, Alexander S et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001; 72: 13-21.
25. Boots JM, Christiaans MH, Van Duijnhoven EM, Van Suylen RJ, Van Hooff JP. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation 2002; 74: 1703-9.
26. Calne R, Moffatt SD, Friend PJ, Jamieson NV, Bradley JA, Hale G. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68: 1613-6.
27. Cecka MJ. The UNOS Scientific Renal Transplant Registry. In: Cecka JM, Terasaki PI (eds): Clinical Transplants. Los Angeles, CA: UCLA Tissue Typing Laboratory, 2000: 1-20.
28. Almawi WY, Melemedjian OK, Rieder MJ. An alternate mechanism of glucocorticoid anti-proliferative effect: promotion of a Th2 cytokine-secreting profile. Clin Transplant 1999; 13: 365-74.
29. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62: 1060-1067.
30. Van Duijnhoven EM, Boots JM, Christiaans MH, Stolk LM, Undre NA, Van Hooff JP. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 2003; 16: 721-725.
31. Hjelmesaeth J, Hartmann A, Kofstad J et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979-83.
32. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185.
33. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977-983.
34. Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 61: 1576-1581.
35. Cantarovich D, Giral-Classe M, Hourmant M et al. Low incidence of kidney rejection after simultaneous kidney-pancreas transplantation after antithymocyte globulin induction and in the absence of corticosteroids: results of a prospective pilot study in 28 consecutive cases. Transplantation 2000; 69: 1505-1508.
36. Kaufman DB, Leventhal JR, Koffron AJ et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2002; 73: 169-177.
37. Brennan DC, Flavin K, Lowel JA et al. A randomized double-blind comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011-1018.
38. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003; 326: 789.
39. Margreiter R for the European Tacrolimus vs. Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomized multicentre study. Lancet 2002; 359: 741-746.
40. MacDonald AS, for the Rapamune Global Study Group. A worldwide phase III randomized, controlled safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2000; 71: 271-280.
41. Kahan BD for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202.
42. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39-47.
43. Ahsan N, Johnson C, Gonwa T et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: Results at 2 years. Transplantation 2001; 72: 245-250.